1. Preface

   • Yutaka Ariyoshi
   • Tetsuya Mitsudomi
   • Ryuzo Ueda

   OriginalPaper 09 November 2006 Pages: 1 - 3

2. Impact of EGFR mutations on treatment of non-small cell lung cancer

   • Bruce E. Johnson
   • David Jackman
   • Pasi A. Jänne

   OriginalPaper 09 November 2006 Pages: 5 - 9

3. Defining clinically relevant molecular subsets of lung cancer

   • William Pao

   OriginalPaper 09 November 2006 Pages: 11 - 15

4. Molecular classification of tumors with special reference to EGFR mutation in lung cancer

   • Yasushi Yatabe

   OriginalPaper 09 November 2006 Pages: 17 - 23

   

5. The impact and role of EGFR gene mutation on non-small cell lung cancer

   • Shinichi Toyooka
   • Junichi Soh
   • Hiroshi Date

   OriginalPaper 09 November 2006 Pages: 25 - 31

   

6. Clinical development of EGFR-tyrosine kinase inhibitors in Japan

   • Kazuhiko Nakagawa

   OriginalPaper 09 November 2006 Pages: 33 - 37

   

7. EGFR mutation in various tissues

   • Kazuto Nishio
   • Tokuzo Arao
   • Hideyuki Yokote

   OriginalPaper 09 November 2006 Pages: 39 - 41

8. A randomized phase III trial of adjuvant treatment for resected non-small cell lung cancer in Japan

   • Yukito Ichinose

   OriginalPaper 09 November 2006 Pages: 43 - 48

   

9. Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm

   • Neil P. Shah

   OriginalPaper 09 November 2006 Pages: 49 - 53

10. Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor

    • Shinya Kimura
    • Tomoko Niwa
    • Taira Maekawa

    OriginalPaper 09 November 2006 Pages: 55 - 61

    

11. RNAi, microRNAs, and human disease

    • Scott M. Hammond

    OriginalPaper 09 November 2006 Pages: 63 - 68

    

12. An endothelium-derived angiogenesis inhibitor vasohibin and its significance in tumor angiogenesis

    • Yasufumi Sato

    OriginalPaper 09 November 2006 Pages: 69 - 72